Persistent varices in cured patients: Understanding the role of hepatic venous pressure gradient
Pol Olivas,
Alexandre Soler-Perromat,
Luis Tellez,
José Antonio Carrión,
Edilmar Alvarado-Tapias,
José Ferrusquía-Acosta,
Sabela Lens,
Antonio Guerrero,
Ángeles Falgà,
Pamela Vizcarra,
Lara Orts,
Valeria Perez-Campuzano,
Sarah Shalaby,
Sonia Torres,
Anna Baiges,
Fanny Turon,
Juan Carlos García-Pagán,
Ángeles García-Criado,
Virginia Hernández-Gea
Affiliations
Pol Olivas
Barcelona Hepatic Hemodynamic Laboratory, Liver Unit, Hospital Clínic, Fundacióde Recerca Clínic Barcelona - Institut de Investigacions Biomèdiques August Pi i Sunyer (FRCB-IDIBAPS), Barcelona, Catalonia, Spain; Centro de Investigación Biomédica Red de Enfermedades Hepáticas y Digestivas (CIBEREHD), Madrid, Spain; Health Care Provider of the European Reference Network on Rare Liver Disorders (ERN-RareLiver); Depertament de Medicina i Ciències de la Salut, Universitat de Barcelona, Barcelona, Spain
Alexandre Soler-Perromat
Radiology Department, CDI, Hospital Clínic de Barcelona, Universitat de Barcelona, Barcelona, Spain
Luis Tellez
Centro de Investigación Biomédica Red de Enfermedades Hepáticas y Digestivas (CIBEREHD), Madrid, Spain; Servicio de Gastroenterología y Hepatología, Hospital Universitario Ramón y Cajal, Instituto Ramón y Cajal de Investigación Sanitaria (IRYCIS), Universidad de Alcalá, Madrid, Spain
José Antonio Carrión
Liver Section, Gastroenterology Department, Hospital del Mar, Institut Hospital del mar D’Investigacions Mèdiques, PSMAR, Universitat Pompeu Fabra, Facultat de ciències de la Salut i de la Vida, Barcelona, Spain
Edilmar Alvarado-Tapias
Centro de Investigación Biomédica Red de Enfermedades Hepáticas y Digestivas (CIBEREHD), Madrid, Spain; Gastroenterology Department, Hospital de la Santa Creu I Sant Pau, Institut d’Investigacions Biomèdiques Sant Pau, Barcelona, Spain
José Ferrusquía-Acosta
Centro de Investigación Biomédica Red de Enfermedades Hepáticas y Digestivas (CIBEREHD), Madrid, Spain; Unitat Hepatologia, Servei Aparell Digestiu, Hospital Universitari Parc Taulí, Institut d’Investigació i Innovació Parc Taulí (I3PT), Sabadell, Spain
Sabela Lens
Barcelona Hepatic Hemodynamic Laboratory, Liver Unit, Hospital Clínic, Fundacióde Recerca Clínic Barcelona - Institut de Investigacions Biomèdiques August Pi i Sunyer (FRCB-IDIBAPS), Barcelona, Catalonia, Spain; Centro de Investigación Biomédica Red de Enfermedades Hepáticas y Digestivas (CIBEREHD), Madrid, Spain; Depertament de Medicina i Ciències de la Salut, Universitat de Barcelona, Barcelona, Spain
Antonio Guerrero
Centro de Investigación Biomédica Red de Enfermedades Hepáticas y Digestivas (CIBEREHD), Madrid, Spain; Servicio de Gastroenterología y Hepatología, Hospital Universitario Ramón y Cajal, Instituto Ramón y Cajal de Investigación Sanitaria (IRYCIS), Universidad de Alcalá, Madrid, Spain
Ángeles Falgà
Barcelona Hepatic Hemodynamic Laboratory, Liver Unit, Hospital Clínic, Fundacióde Recerca Clínic Barcelona - Institut de Investigacions Biomèdiques August Pi i Sunyer (FRCB-IDIBAPS), Barcelona, Catalonia, Spain; Health Care Provider of the European Reference Network on Rare Liver Disorders (ERN-RareLiver)
Pamela Vizcarra
Barcelona Hepatic Hemodynamic Laboratory, Liver Unit, Hospital Clínic, Fundacióde Recerca Clínic Barcelona - Institut de Investigacions Biomèdiques August Pi i Sunyer (FRCB-IDIBAPS), Barcelona, Catalonia, Spain; Health Care Provider of the European Reference Network on Rare Liver Disorders (ERN-RareLiver)
Lara Orts
Barcelona Hepatic Hemodynamic Laboratory, Liver Unit, Hospital Clínic, Fundacióde Recerca Clínic Barcelona - Institut de Investigacions Biomèdiques August Pi i Sunyer (FRCB-IDIBAPS), Barcelona, Catalonia, Spain; Centro de Investigación Biomédica Red de Enfermedades Hepáticas y Digestivas (CIBEREHD), Madrid, Spain; Health Care Provider of the European Reference Network on Rare Liver Disorders (ERN-RareLiver)
Valeria Perez-Campuzano
Barcelona Hepatic Hemodynamic Laboratory, Liver Unit, Hospital Clínic, Fundacióde Recerca Clínic Barcelona - Institut de Investigacions Biomèdiques August Pi i Sunyer (FRCB-IDIBAPS), Barcelona, Catalonia, Spain; Centro de Investigación Biomédica Red de Enfermedades Hepáticas y Digestivas (CIBEREHD), Madrid, Spain; Health Care Provider of the European Reference Network on Rare Liver Disorders (ERN-RareLiver)
Sarah Shalaby
Barcelona Hepatic Hemodynamic Laboratory, Liver Unit, Hospital Clínic, Fundacióde Recerca Clínic Barcelona - Institut de Investigacions Biomèdiques August Pi i Sunyer (FRCB-IDIBAPS), Barcelona, Catalonia, Spain; Centro de Investigación Biomédica Red de Enfermedades Hepáticas y Digestivas (CIBEREHD), Madrid, Spain; Health Care Provider of the European Reference Network on Rare Liver Disorders (ERN-RareLiver)
Sonia Torres
Barcelona Hepatic Hemodynamic Laboratory, Liver Unit, Hospital Clínic, Fundacióde Recerca Clínic Barcelona - Institut de Investigacions Biomèdiques August Pi i Sunyer (FRCB-IDIBAPS), Barcelona, Catalonia, Spain
Anna Baiges
Barcelona Hepatic Hemodynamic Laboratory, Liver Unit, Hospital Clínic, Fundacióde Recerca Clínic Barcelona - Institut de Investigacions Biomèdiques August Pi i Sunyer (FRCB-IDIBAPS), Barcelona, Catalonia, Spain; Centro de Investigación Biomédica Red de Enfermedades Hepáticas y Digestivas (CIBEREHD), Madrid, Spain
Fanny Turon
Barcelona Hepatic Hemodynamic Laboratory, Liver Unit, Hospital Clínic, Fundacióde Recerca Clínic Barcelona - Institut de Investigacions Biomèdiques August Pi i Sunyer (FRCB-IDIBAPS), Barcelona, Catalonia, Spain; Centro de Investigación Biomédica Red de Enfermedades Hepáticas y Digestivas (CIBEREHD), Madrid, Spain; Health Care Provider of the European Reference Network on Rare Liver Disorders (ERN-RareLiver)
Juan Carlos García-Pagán
Barcelona Hepatic Hemodynamic Laboratory, Liver Unit, Hospital Clínic, Fundacióde Recerca Clínic Barcelona - Institut de Investigacions Biomèdiques August Pi i Sunyer (FRCB-IDIBAPS), Barcelona, Catalonia, Spain; Centro de Investigación Biomédica Red de Enfermedades Hepáticas y Digestivas (CIBEREHD), Madrid, Spain; Health Care Provider of the European Reference Network on Rare Liver Disorders (ERN-RareLiver); Depertament de Medicina i Ciències de la Salut, Universitat de Barcelona, Barcelona, Spain
Ángeles García-Criado
Radiology Department, CDI, Hospital Clínic de Barcelona, Universitat de Barcelona, Barcelona, Spain
Virginia Hernández-Gea
Barcelona Hepatic Hemodynamic Laboratory, Liver Unit, Hospital Clínic, Fundacióde Recerca Clínic Barcelona - Institut de Investigacions Biomèdiques August Pi i Sunyer (FRCB-IDIBAPS), Barcelona, Catalonia, Spain; Centro de Investigación Biomédica Red de Enfermedades Hepáticas y Digestivas (CIBEREHD), Madrid, Spain; Health Care Provider of the European Reference Network on Rare Liver Disorders (ERN-RareLiver); Depertament de Medicina i Ciències de la Salut, Universitat de Barcelona, Barcelona, Spain; Corresponding author. Address: Barcelona Hepatic Hemodynamic Laboratory, Liver Unit, Hospital Clínic, Villarroel 170, Barcelona 08036, Spain. Tel.: +34932275400 (2209); Fax: +34-932279856.
Background & Aims: Etiologic factor removal (ER) drives recompensation and improves portal hypertension in cirrhosis. Esophageal varices (EV) and portosystemic shunts (PSS) have been found in patients despite hepatic venous pressure gradient (HVPG) dropping below 10 mmHg after ER, questioning HVPG accuracy in reflecting true portal pressure in the setting of ER. We aim to evaluate the correlation of HVPG with direct portal pressure (DPP) in patients with persistence of EV after ER despite HVPG <10 mmHg. Methods: This is a bicentric ‘proof of concept’ study evaluating HVPG and ultrasound-guided percutaneous DPP in patients with HCV or alcohol-related cirrhosis with persistent varices and HVPG <10 mmHg after at least 5 years of ER. Results: Seven patients with HCV and three with alcohol-related cirrhosis with persistent varices and HVPG <10 mmHg after at least 5 years of ER were included. At evaluation, all patients had a patent portal vein and were compensated. The median platelet count was 129.5 (IQR 95–145) × 109/ml, and the median liver stiffness measurement was 16.15 (IQR 14.4–22.3) kPa. In five patients, EV remained the same size (two large and three small), and five downsized to small after ER. Wedge hepatic vein pressure (median 19 [IQR 16.5–20] mmHg) and portal pressure (median 18 [IQR 15–19.5] mmHg) had an excellent correlation (R = 0.93, p <0.0001). Portal pressure gradient (PPG) confirmed the absence of clinically significant portal hypertension as identified by HVPG across all the patients. Conclusions: HVPG accurately reflects PPG in the context of HCV and alcohol-related cirrhosis regression. After ER, EV may persist despite HVPG <10 mmHg. The benefit of prophylaxis in patients with EV and HVPG <10 mmHg is unknown. Future studies with clinical endpoints are needed to validate our findings. Impact and implications:: Despite a favorable evolution after the removal of the etiologic factor, varices persist in some patients, and there is a lack of concise guidelines for the evaluation and management of portal hypertension in this population. Our research underscores the persistence of varices in the absence of clinically significant portal hypertension and significantly demonstrates the accuracy of hepatic venous pressure gradient (HVPG) in reflecting portal vein pressure in this specific patient group. These findings emphasize the crucial role of HVPG in the assessment of portal hypertension after etiologic factor removal and lay the groundwork for further investigation into clinical outcomes and the necessity of non-selective beta-blockers in individuals with persistent varices after the removal of etiologic factor.